Computational Biology Market Share

North America Market Insights

North America in the computational biology market is projected to hold the largest share of 42.2% by the end of 2035. The market’s growth in the region is highly propelled, owing to its demand across research and academic facilities for different drug discovery and development, along with the presence of a strong U.S. biotechnology and biopharmaceutical sector. As per the April 2022 NLM article, the U.S. FDA increased its approval track for personalized medicine in the region from 21% to 39% within the past 5 years. In addition, regional strategies have been unveiled to provide back-up for personalized medicine through translation and research, along with the provision of government investment of USD 4 billion, thereby suitable for the market’s growth.

The market in the U.S. is also significantly growing, owing to generous funding allocation. According to an article published by the U.S. Department of Energy in August 2023, the organization declared the provision of USD 4.7 million for 5 latest research projects, pertaining to computational biology. The purpose was to assist these projects in developing cutting-edge analytical and software tools and administer the increased quantities of genomics, originating from biological systems and microbes. In addition, the Biological and Environmental Research (BER) Genomic Science program utilizes the genome, which has effectively enabled approaches to recognize basic principles to drive biological systems in the country.

The market in Canada is also growing, owing to contributions initiated by the government through budget provision, particularly for genomics strategy. In this regard, as per the February 2025 Heath Canada report, there has been a commitment of more than USD 1.6 billion for more than 20 years through Genome Canada's funding, especially for large-scale applied and translational genomics. Besides, to support the country’s robust support for genomics translation and research, the government of Canada has allocated USD 175.1 million for more than 7 years to effectively back the regional Genomics Strategy, thus suitable for boosting the market in the country.

Source: U.S. FDA, June 2025

APAC Market Insights

Asia Pacific in the computational biology market is expected to emerge as the fastest-growing region, accounting for approximately 22.3% of the share during the forecast timeline. The market’s upliftment is highly attributed to the increased growth in the region’s biopharmaceutical industries, including India and China, which has further resulted in increased investments for the life science and healthcare sectors. According to the January 2025 Asia Development Organization, over 20 countries in the region constitute more than 20% risk of people suffering death due to chronic conditions. Besides, an early screening program was conducted in Mongolia, catering to 40% of the population as of 2023 to reduce stomach cancer, thus denoting a prolific opportunity for the market in the region.

The market in China is gaining increased traction, owing to the existence of administrative bodies approving drugs through biological research. According to the April 2025 NLM article, only 79 drugs were approved in the country over the past 11 years, and its international share of innovative drugs was 3% as of 2021. Besides, the National Medical Products Administration (NMPA) as of 2023 cleared 256 latest drugs through intense research, which in turn, is bolstering the market in the country. In addition, Class I innovative drug approvals reached 101 in the same year, along with the addition of 33, thereby denoting a 136% surge in the overall country.

The market in India is also gaining increased traction, owing to its implementation for aiding diabetes. According to a report published by the PIB in August 2023, the incidence of diabetes is 10.1 crores (1.1 million). However, to combat this, the Department of Health & Family Welfare, Government of India, provides financial and technical support to different states. Besides, the October 2022 Heliyon report stated that over the past 8 years household earnings in the country accounted for 5% to 25% of the share, along with an expenditure of USD 31 billion, thereby enhancing the market’s demand.

Percentage of Deaths in APAC Between 30 to 70 Years from CVD

Source: Asian Development Blog Organization, June 2025

Europe Market Insights

Europe in the computational biology market is estimated to hold a considerable share of 27.5% by the end of the projected timeline. The market’s upliftment in the region depends on catering to severe challenges in healthcare, with increased focus on personalized medicine and drug delivery, along with managing complicated biological systems. Besides, as per the April 2025 NPJ report, there have been two initiatives, including the European Health Data Space (EHDS), which has covered 449 million of the population, as well as Germany’s forthcoming Health Data Lab, which has gathered data accessibility from 75 million insured patients, which is 90% of the country’s population. Therefore, these two strategies are effectively bolstering the market’s growth in the region.

The market in the UK is steadily gaining exposure, owing to the provision of healthcare budget. According to a report published by the UK Research and Innovation in March 2025, there has been an establishment of the Synthetic Biology for Growth programme by research councils in the country to allocate a budget of £102 million. This budget has been provided after achieving recommendations on biologic investment and research from the UK government. It comprises 4 main investment streams, including DNA synthesis, suitable training for students, synthetic biology seek fund, and multidisciplinary Synthetic Biology Research Centres (SBRCs).

The market in Germany is also growing due to an increase in the presence of doctors and hospitals. Based on this, the April 2025 NPJ report indicated that currently 430,000 doctors and 1,900 hospitals are focusing on the population, with a cost of over €1 billion per day, which accounts for 10% of the country’s gross domestic product (GDP). Besides, the 2025 Statistisches Bundesamt report denotes an increase in the overall health expenditure to €474.1 billion, accounting for €5,699 per inhabitant. In addition, the report also noted that there has been a surge in the country’s expenditure to €6,013, thereby denoting an upsurge in the market’s demand.